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Accepted 12 March 2012AbstractSystemic administration of cytotoxic drugs is the primary treatment strategy for patients with advanced cancer. The effect of cytotoxic drugs
is to disrupt the DNA of the cells, rendering them unable to replicate and finally killing them; therefore, the fundamental role of a wide range of
treatment regimens is typically to induce lethal toxicity in the largest possible number of cancer cells. However, these cytotoxic drugs also
damage the normal cells of the host, which limits the dose of the cytotoxic drug. Thus, cancer patients are usually treated at or near the maximum
tolerated dose with the implicit intent of eradicating (curing) the tumor after balancing between efficacy in tumor killing and toxicity to the host.
With significantly improving patient care, most efforts are focused on the corollary, “The higher the dose, the better.” However, the concept that
cancer could be considered as a chronic disease and might be treated like other chronic diseases to achieve a status called tumor dormancy is
gaining popularity. In addition, there has been increasing interest in putting more effort into administering cytotoxic drugs on a more continuous
basis, with a much shorter break period, or none at all, and generally lower doses of various cytotoxic drugs or combinations with other newer,
targeted therapies, like anti-angiogenesis agents. This practice has come to be known as metronomic chemotherapy. There is still much to be
learned in this field, especially with regard to optimization of the proper drugs, dose, schedule, and tumor type applications. This review will
explore recent studies that have addressed the mechanism of metronomic chemotherapy in the management of various tumors, especially
gynecologic cancers.
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Gynecologic oncology has advanced dramatically over the
past few decades, and physicians have seen the successful
application of a number of conventional cytotoxic drugs to
cancer conditions diagnosed in their female patients. Among
these cancers, epithelial ovarian cancer (EOC) might be one of
the best examples. Advances in surgical technique, anesthesia
support, and intensive postoperative care significantlycs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.




Fig. 1. Different chemotherapy regimens. Metronomic chemotherapy regimens
differ from the standard MTD chemotherapy regimens that have been
commonly used in medical oncology for decades. (A) In conventional
chemotherapy a drug is typically given in a single bolus injection or infusion at
the MTD, followed by a long break, for example, 3 weeks, before the next
course of this therapy is administered; (B and C) examples of metronomic
schedules are shown, in which, for example, the chemotherapy drug is
administered more frequently, such as weekly (B), with no prolonged drug-free
interruptions. Targeted drugs, including small molecule drugs, monoclonal
antibodies, apoptosis-inducing drugs, angiogenesis inhibitors and low-dose
chemotherapy, are mainly prescribed on a daily basis (C); (D) combined
therapy is then ideal for the two schedules (B and C) in a chronic administration
manner. MTD ¼ maximum tolerated dose.
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alone cannot treat diseases such as EOC successfully, even
after aggressive surgical intervention, partly because of the
presence of some residual tumor and partly because of the
high recurrence of tumors; therefore, adjuvant postoperative
chemotherapy with cytotoxic drugs is nearly always needed to
attempt to gain complete clinical remission [2].
EOC was one of the first solid tumors to have a chance of
being successfully controlled with cytotoxic drugs, although
the disease-free interval is short [3]. The fundamental goal of
cytotoxic drugs is typically to induce lethal toxicity in the
largest possible number of tumor cells; therefore, most
research efforts in chemotherapy are focused on discovery of
agents and combinations of agents, doses, and dose schedules
that maximally kill tumor cells while minimizing the toxicity
to the host [4].
Although more than 80% of patients with advanced EOC
receiving a combination of platinum and paclitaxel as primary
chemotherapy initially responded, most of them developed
resistant disease [5]. Only in rare cases, for example, chorio-
carcinoma and germ cell tumors of the ovary [6], cures can be
achieved.
The use of drug regimens that have been designed to kill as
many tumor cells as possible by treating with the maximum
tolerated doses (MTDs) of these cytotoxic agents have been
challenged in EOC recently, although dose-intensity strategy
through intraperitoneal route has been reported in success.
Moreover, side effects, such as neurotoxicity and damage to
proliferating cells in healthy tissues pose serious constraints on
the use of chemotherapy based on MTDs [7]. To allow these
susceptible normal tissues like intestinal epithelium and bone
marrow cells to heal, a drug-free break period before the next
dose of chemotherapy is always scheduled [8]. This break
period can be as lengthy as 3e4 weeks or more, depending on
which cytotoxic drug or combinations are used. This practice
not only involves the re-growth of tumor cells, but also growth
of selected clones resistant to the agents [9]. Therefore, the
patient’s tolerance is believed to be one of the key factors in
this kind chemotherapy. The minimal cure rate at a such a high
price had made us reconsider the feasibility of MTD-based
chemotherapy [10].
The bothersome side effects of cytotoxic chemotherapy
include myelosuppression, hair loss, intestinal mucosa
damage, nausea, vomiting, and mucositis, not to mention the
long-term cardiac (for example, adriamycin), renal (for
example, cisplatin), neurologic (for example, cisplatin, and
paclitaxel), and reproductive (for example, cyclophosphamide)
consequences, including premature ovarian failure [11,12].
Indeed, many of the recent pharmacological advances in
cancer treatment involve growth factors and antinausea drugs,
which are administered to cancer patients to minimize the
severity of, or accelerate recovery from chemotherapy-induced
toxicities, but such “supportive-care drugs” can significantly
add to the financial burden of cancer chemotherapy, and have
their own side effects [10].
To minimize the toxicity of MTD regimens and improve
the anti-tumor effect, the future success of chemotherapymight be dependent on the integration of the metronomic
scheduling of cytotoxic chemotherapy [10] and more targeted
approaches [8]. Instead of only using short bursts of toxic
MTD chemotherapy interspersed with long breaks to allow
recovery from the harmful adverse events, there is now a shift
in thinking towards the view that more compressed or accel-
erated schedules of drug administration using much smaller
individual doses than the MTD would be more effective [13].
Much smaller individual doses separated by a short or very
short interval not only reduce certain toxicities, but perhaps
even improve the anti-tumor effects as well [14,15]. In addi-
tion, some of these dosing and/or scheduling strategies are
ideally suited to combining chemotherapeutics with many of
the new targeted and relatively non-toxic anticancer drugs that
have been or are being developed [10].
A new strategy to administer cytotoxic cancer therapy
The term “metronomic” refers mainly to the scheduling,
which consists of chronic, equally spaced, and generally low
doses of single or combined chemotherapeutic drugs without
extended drug-free breaks [9]. Chemotherapy is convention-
ally prescribed at the highest level that is tolerated by the
patient, in order to provide the possibility of eradicating the
cancer cells (Fig. 1). The evidence supporting this hypothesis
is derived from the work of Skipper and colleagues [16], who
utilized an in vitro cancer cell culture system to demonstrate
the logarithmic tumor cell kill rate with increasing chemo-
therapeutic doses. Application of these findings to certain
hematologic cancers, or “liquid tumors”, such as leukemia or
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inapplicable to the majority of solid tumors that exist within
a complex microenvironment, consisting of stromal cells,
immune cells, blood vessels, and many other interacting
components that influence tumor biology [8,14,17].
Many factors have contributed to the emergence of new
concepts in chemotherapy. First, as mentioned above, the
MTD approach has failed to provide the expected survival
benefits, therefore the concept of “the higher the better” has
been challenged by “the more frequent the better” [18,19].
More and more evidence from randomized Phase III clinical
trials has shown that ‘dose-dense’ chemotherapy, in which one
or more chemotherapeutics are administered at more frequent
intervals (that is, every other week), has clear benefits
[10,20e22]. This strategy is actually designed to administer at
least the same amount or, more commonly, even a greater
amount of the drug, in total, over time [10,20].
Second, the concept that cancer is a chronic disease and
should be treated like other chronic diseases” was proposed by
Fidler and Ellis in 2000 [23]. Control of cancer was expected
to be just like control of diabetes, though it might be more
critical and complicated. The strategy of "treatment-for-cure"
is gradually being replaced by "treatment-for-stability” to
maximize the survival of victims with advanced cancers.
Furthermore, to avoid the toxicities and morbidity caused
by conventional chemotherapeutic regimens and improve the
life quality of cancer patients, several groups had studied
a new modality of drug administrationdmetronomic therapy
[9], a term first used by Douglas Hanahan [7], who also
emphasized the concept of “less is more” instead of “the
higher the better,” and demonstrated the antiangiogenic effect
of metronomic dosing of cytotoxic agents in mice. This
schedule was then defined as a special type of treatment with
chronic use of cytotoxic chemotherapeutic agents at lower and
less toxic doses (Fig. 1).
Finally, a new class of chemotherapeutics called targeted
therapy drugs was viewed as a potential solution for cancer
treatment [24]. Since these drugs were designed to attack
cancer cells using a specific marker or a particular pathway,
such as angiogenesis, for cancer survival, their toxicity to the
host was limited and their use could be continuous, just like
the scheduled application in metronomic chemotherapy
(Fig. 1). The combination of targeted therapy and metronomic
chemotherapy was believed to be more effective in advanced
cancers [25], and yield a better survival rate (Fig. 1).
Mechanism of metronomic therapy
Although the exact mechanism remains unclear, the reason
why metronomic chemotherapy works might be vasculature-
related and based on a concept proposed by Judah Folkman
and Robert Kerbel [25,26], who were pioneers in making this
proposal for a change in the way with which chemotherapy is
undertaken. In 1971, Folkman [27] first articulated the concept
of what he called “antiangiogenic” agents. Based on observa-
tions that expansion of a tumor mass was limited in the absence
of angiogenesis, he proposed that treatment with drugs thatprevent the formation of tumor blood vessels might be able to
constrain or starve cancer cells eventually [27]. Kerbel’s group
[10] further demonstrated the antitumor efficacy of using some
of the most widely used cytotoxic drugs. When given contin-
uously in low doses, these agents showed anti-angiogenic
effects, and were a promising therapeutic choice for treating
tumors that no longer responded to conventional chemotherapy
[10] with limited or no toxicity [28].
The success of metronomic therapy is currently believed to
rely on three main mechanisms: continuous administration,
activation of cancer immunology, and antiangiogenic effects
[8]. First, tumor cells could be exposed to the drug more
continuously by diminishing the drug-free period that
accompanies MTD regimens. As in radiation therapy,
a continuous low-dose schedule might permit more efficient
cancer cell destruction as cells continue to proliferate or enter
into the growth cycle [8]. There would be significantly less
opportunity for repair of the damaged endothelial cells or
tumor cells and the anti-tumor effects of the chemotherapy
would irreversibly accumulate in a metronomic regimen.
Second, the tumor escaping from the surveillance of host
immunity might play a role in cancer development [29].
Instead of the deleterious myelosuppression induced by MTD
chemotherapy, certain cytotoxic drugs in metronomic sched-
ules display immune-stimulatory effects that can enhance the
immune response to cancer antigens [30].
Finally, and most importantly, inhibition of tumor angio-
genesis was demonstrated to be the main effect of metronomic
chemotherapy [31]. Angiogenesis is the process of establishing
a new circulation system, which involves the recruitment of
sprouting vessels from existing blood vessels and incorporation
of endothelial progenitors into the growing vasculature [32].
This process of new blood vessel growth that occurs in a variety
of physiologic and pathophysiologic states [33e36] not only
brings forth oxygen and nutrients, but also removes wastes. A
prosperous blood supply network is fundamental for a solid
tumor to grow beyond severalmillimeters in diameter [8]. These
“activated” endothelial cells of newly forming capillaries in
cancer demonstrated high and selective sensitivity to very low
doses of various chemotherapeutic agents in vitro [10]. Several
studies have used very low concentrations of cytotoxic drugs,
such as vinblastine [37, injectable taxanes [38], and paclitaxel
[39] to test various human cells, including microvascular and
macrovascular endothelial cells, and found that these drugs
inhibited the proliferation or migration of endothelial cells, but
not of other cell types that were examined.
These continuous chemotherapeutic schedules have had
effects on at least four specific aspects of angiogenesis
(Fig. 2). The first is the direct cytotoxic effect on the endo-
thelial cells of the blood vessels (Fig. 2A). With an outcome
not possibly achieved with a conventional schedule, Browder
and colleagues [40] demonstrated that metronomic use of
cyclophosphamide suppressed certain tumor growth threefold
more effectively. Though it is not so easy to differentiate the
detrimental effects between the tumor population and angio-
genic progenitor cell population, which mix in general
homogenously or heterogeneously, and it is relatively simple
Fig. 2. Four specific aspects of angiogenesis have been shown to be impacted
by these continuous cytotoxic chemotherapeutic schedules, including (A)
direct damage to endothelial cells; (B) alteration of the balance of growth
factors; (C) decrease in the progenitor of endothelial cells from bone marrow;
(D) and inhibition of MMPs. MMP ¼ matrix metalloproteinase.
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showed that the endothelial cells were the first part of the
tumor to undergo apoptosis [26].
The second involves decreasing angiogenesis by an indirect
effect, which is accomplished by a new balance of growth
factors related to angiogenesis that hinder vessel expansion
(Fig. 2B). These events might involve the inhibition of growth
factors like vascular endothelial growth factor (VEGF), basic
fibroblastic growth factor (bFGF), epidermal growth factor
(EGF), platelet-derived growth factor (PDGF) and
cyclooxygenase-2 (COX-2), or damage to relevant receptors.
Bocci’s group [41] found that selective inhibition of human
endothelial-cell proliferation or induction of apoptosis was
detected only after a prolonged exposure to very low
concentrations of a number of different chemotherapeutic
drugs, including taxanes and alkylating agents. This delay
showed that the cytotoxic effects of low-dose metronomic
chemotherapy on endothelial cells might not be direct, but
could be a secondary result of some other process that is
specific to the vascular endothelial cell [10].
Third, the expansion of tumor blood vesselsmay also rely on,
or at least be influenced by, recruitment of bone mar-
rowederived endothelial progenitor cells [8]. A decrease in the
levels and viability of endothelial progenitor cells was docu-
mented after metronomic chemotherapy [42]. Adverse effects
on these cells resulted in decreased angiogenesis (Fig. 2C).
Finally, the action of matrix metalloproteinases (MMPs),
which are enzymes that break down extracellular matrix to
allow room for migration of endothelial cells to form blood
vessels, may also be blocked by these agents [34]. This will
also limit new vessel development and further expansion of the
cancer (Fig. 2D).
Metronomic therapy used in gynecologic cancers
Several metronomic regimens of cytotoxic agents were
used to rescue patients with advanced or refractory gyneco-
logic cancers. Metronomic use of chemotherapy was mainly
focused on recurrent EOC, however, high fractions and low
dose-rate radiotherapy for advanced cervical cancer was
viewed as metronomic radiotherapy and included below.Epithelial ovarian cancerOver the past few decades, a number of conventional
cytotoxic drugs have been successfully used with EOC
patients. Although adjuvant postoperative chemotherapy with
cytotoxic drugs allows nearly all patients with EOC to achieve
complete clinical remission [2], the disease-free interval is
short and often transient [3]. In addition, the high rate of
resistance and the massive toxicity of this regimen pave the
way for a metronomic regimen.CyclophosphamideThe antiangiogenic action of metronomic use of this agent
was first demonstrated in a murine model of
cyclophosphamide-resistant tumors designed to rescue mice
by inducing endothelial apoptosis [26]. Metronomic dosage of
oral CTX (20 mg/kg/day), combined with injected irinotecan
(10 mg/kg, twice a week), cisplatin (1 mg/kg, twice a week) or
paclitaxel (1 mg/kg, three times a week) in mice was proved to
be safe, though not very effective in this mice model [43].
However, the use of low-dose oral CTX was recommended
as a potential strategy against tumor progression in platinum-
resistant patients with resistant EOC after standard chemo-
therapy and with a poor performance status [44].
Metronomic therapy using low-dose CTX could be
combined with oral 5-FU [45] or an antiangiogenic drug,
bevacizumab (10 mg/kg intravenously, every 2 weeks), and
proved to be safe and effective in recurrent EOC patients [46],
even in patients with failed chemotherapy using cisplatin,
gemcitabine, topotecan and liposomal doxorubicin chemo-
therapy [47,48].TopotecanA dosage of 1.5 mg/M2 infusion for more than 30 minutes
on 5 consecutive days every 5 weeks is recommended in
a MTD regimen for ovarian cancer. A continuous low dose of
irinotecan (10 mg/kg) was proved to be safe and effective in
a mice model of ovarian cancer [43]. A metronomic regimen
of topotecan (1.0 mg  0.5 mg once every day (qd)) showed
promise in an advanced EOC cell model through its anti-
vascular effect [49]. Oral topotecan (25 mg/day twice every
day (bid) or 100 mg/kg/day) has demonstrated a positive effect
against ovarian cancer in mice, especially when combined
with an anti-angiogenic drug, pazopanib (150 mg/kg/d) [43].
However, a high drop-out rate (6/13) was noted in a test using
oral topotecan with a metronomic dosage as low as 0.3 mg/m2
twice daily for 21 consecutive days out of 28. Severe side
effects like hematologic toxicity and diarrhea still occurred in
these patients with advanced EOC. The appropriate dose and
schedule of this agent used in a metronomic regimen for
humans are still worth studying [50].TaxanesThe usual dosage of paclitaxel as an adjuvant chemo-
therapy for EOC is 135 mg/M2 every 3 weeks. Lower-dose
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a metronomic combination in a mice ovarian cancer model,
with minimal toxicity and a potential effect [43]. Metronomic
taxanes (0.5 mg/kg, twice weekly) alone and in combination
with oral AEE788 (50 mg/kg, twice weekly)da dual EGF
receptor (EGFR) and VEGF receptor (VEGFR) inhib-
itordwere used in an orthotopic mouse model of EOC and
also showed promising effectiveness [51].CisplatinA lower dose of cisplatin (1 mg/kg, twice weekly) was used
in combination with other cytotoxic agents in mice with
proved safety and efficiency [43]. Since platinum was usually
included in the MTD chemotherapy regimen (100e200 mg/
M2, 2e6 hours every 3e4 weeks) as the first-line adjuvant
therapy for ovarian cancer, the fact that there are limited
reports about this regimen for recurrent ovarian cancer is
reasonable. However, metronomic cisplatin still revealed anti-
angiogenic and anti-tumor effects in a rat model [52], and has
been used with other cancers like colon or lung cancer.5-fluorouracil (5-FU)Metronomic use of this agent (24e120 mg/kg/week)
showed an antiangiogenic effect and resulted in body weight
increase in a rat model [52]. An oral 5-FU prodrug (UFT),
when used in a metronomic way and combined with oral CTX
and bevacizumab, an anti-VEGF monoclonal antibody,
showed encouraging results in recurrent ovarian cancers [45].Uterine cancerThere is a limited amount of literature on metronomic
therapy focusing on uterine sarcoma. Metronomic doxi-
fluridine alone significantly suppressed the growth of human
uterine carcinosarcoma cells and reduced intratumoral vascu-
larity, while metronomic doxifluridine in combination with
TNP-470 significantly inhibited tumor growth and vascularity
compared with each treatment alone [53]. Metronomic irino-
tecan (4 mg/day) combined with low-intensity ultrasound
(2.0 w/cm2, 1 MHz) for 4 minutes three times per week
showed more potential effect in the treatment of human uterine
sarcoma than each treatment alone [54].
Metronomic scheduling of cytotoxic drugs, when combined
with imatinib mesylate (Gleevec; Novartis Pharmaceuticals
Corp., East Hanover, NJ, USA) showed a promising effect on
uterine malignancy [55].Cervical cancerIf we view radiotherapy as an agent for cancer treatment,
high fractions and a low dose rate (LDR) schedule for this
therapy are the origins of the development of the metronomic
regimen. As such, the changing course of radiotherapy for
cervical cancer demands discussion. Compared with EOC,
squamous cell carcinoma of the uterine cervix is moresensitive to radiotherapy, and it has been the treatment of
choice for local advanced cases.
To diminish the local hazard effect and increase the accu-
mulated dosage, several LDR schedules with some modifica-
tion, like pulsed brachytherapy [56] or a continuous LDR
remote after-loading brachytherapy using the Martinez
Universal Perineal Interstitial Template (MUPIT) [57] have
been proposed to achieve fewer adverse events and better
results. Wide ranges of dose rates, from 0.1 cGy/day to several
Gy/minute, have been tested and the equivalent effect of high
and LDR intracavity treatment for carcinoma of the uterine
cervix seemed supported, though several questions remained
to be answered [58]. In addition, more efficient inactivation of
cervical cancer cells at lower (0.33 Gy/hour) rather than at
higher dose rates (0.86 Gy/hour) was observed for radiation
doses exceeding 7 Gy, due to the pre-mitotic accumulation of
cells during LDR irradiation [59].
As for chemotherapeutics used in cervical cancer, platinum
(a continuous low-dose of intra-arterial infusion cisplatin [60]
or a continuous infusion of carboplatin (12 mg/m2/day) [61],
considered to be a radiosensitizer, is the most active single
cytotoxic agent [60]. A continuous LDR of 5 cGy/minute
instead of a higher dose rate of 70 cGy/minute when combined
with four agents, including bleomycin, etoposide, cisplatin,
and ifosfamide, led to substantial additional growth delay in
a mice model [62]. Furthermore, different RT regimens were
combined with chemotherapy to increase tumor radiosensi-
tivity. Hyperfractionated radiotherapy (HFRT, 1.2 Gy in two
daily fractions, totally 60 Gy) with concurrent chemotherapy
(MTD of paclitaxel or cisplatin, weekly) for para-aortic lymph
node (PALN) recurrence of cervical carcinoma was proved to
be effective and safe [63].
However, since concurrent platinum-based (cisplatin, 40
mg/m2, weekly) [64] chemoradiation has become the standard
treatment of choice for locally advanced cervical cancer
patients, even for those after LARVH (laparoscopically
assisted radical vaginal hysterectomy) [65], many recurrent
tumors may therefore be platinum-resistant [66]. And other
synergic drugs like Aurora kinase B inhibitor (ZM447439)
[67], 5-FU (continuous infusion 750 mg/m2, for 5 days every
2 weeks) [68], a prolonged regimen of 5-FU (1000 mg/m2, 24-
hour continuous intravenous infusion, 4 days every 4 weeks)
[69], the polyADP-ribosylation inhibitor, 3-aminobenzamide,
(3-AB, administered at 450 mg/kg) [70], a biweekly PEB
regimen (100 mg/m2 etoposide þ 50 mg/m2 cisplatin þ
50 mg/m2 bleomycin) [71], weekly PEBF (50 mg/m2 etopo-
side þ 20 mg/m2 cisplatin þ 10 mg/m2 bleomycin þ 800 mg/
m2 5-FU, mixed in normal saline, 24-hr continuous iv infu-
sion) [71], and the use of retinoids and interferon [72],
enhance the radio-sensitivity of cervical cancer.
Targeted therapy used in combination with metronomic
therapy in gynecologic cancers
To enhance the success of metronomic therapy in the
management of cancers, other adjunctive drugs targeting the
processes that transform healthy cells into malignant tumors
172 W.-H. Su et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 167e178[24] or different parts of the cancer microenvironment [33]
have been taken into consideration. A new class of drugs
called targeted therapies, including small molecule drugs,
monoclonal antibodies, apoptosis-inducing drugs, angiogen-
esis inhibitors, and cancer vaccines [24] has been under
investigation for adjuvant use in the treatment of various
advanced gynecologic cancers. In fact, the approval of various
antiangiogenic therapeutics for the management of different
advanced malignancy is one of the most significant achieve-
ment in medical oncology practice [45]. A metronomic
schedule made the combination of traditional chemothera-
peutics and these targeted drugs in a continuous and
complementary way and might be proved to be the most
effective regimen [73].
Targeted agents with anti-angiogenic effects may provide
an improvement in the treatment of patients with recurrent
ovarian cancer and may be useful when incorporated into first-
line platinum/taxane therapy [74]. Though the efforts put into
finding a single targeted agent for the treatment of cancer
never stops, these agents, when used alone, demonstrated only
modest efficacy in treating cancer [75,76]. Therefore, the
benefit of these agents may still lie in their ability to combine
safely and efficiently with chemotherapy [76] or radiotherapy
[31]. A detailed review of these targeted agents used in
gynecologic cancers can be found elsewhere [77]. However,
there are a limited number of agents used in combination with
metronomic cytotoxic drugs in gynecologic cancers, and these
agents still mainly act on the angiogenesis process. Strategies
devised to inhibit angiogenesis of malignant tumors includeFig. 3. The specific targets of antiangiogenesis targeted agents. Strategies devised
include (A) neutralization of circulating growth factors with monoclonal antibodies
with small molecular drugs; (D) blockage of NO-related signal pathways of angioge
or following signal transduction. EGF ¼ epidermal growth factor; NO ¼ nitric mneutralization of circulating growth factors, direct inhibition to
receptors, blocking growth factor production, inhibition of
ripped pocket (RTK) activation and suppression of intracel-
lular signaling cascades [31]. The drugs in this group can be
categorized accordingly (Fig. 3) [78].
The VEGF family is comprised of six secreted glycopro-
teins, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and
placenta growth factor [79]. The best-characterized VEGF
family member is VEGF-A (commonly referred to as VEGF.
VEGF status is significantly correlated with neo-
vascularization grade and prognosis in various types of solid
tumors [80] and serves as a predictor of tumor resistance to
various treatments, including radiotherapy and chemotherapy
[36]. Binding of VEGF prevents angiogenesis (Fig. 3A).
The biologic activity of VEGF is dependent on its reaction
with specific tyrosine-kinase receptors called VEGFR [80].
These receptors consist of 3 located on cell membranes and
VEGFR-2, which is predominantly localized on vascular
endothelial cells [81], and mediate the majority of downstream
signal transduction, including the nitrous monoxide pathway
[82] and eventually angiogenesis [79]. Direct damage to the
receptor (Fig. 3B), inhibition of tyrosine kinases (Fig. 3C), or
blockage of the following signal transduction pathway
(Fig. 3D), all have an antiangiogenic effect.
VEGF is produced mainly by malignant cells in response to
events like hypoxia or inflammation, and is stimulated by
substances like growth factors or cytokines, e.g., tumor
necrosis factor alpha (TNF-a), angiopoietin-1 and
angiopoietin-2, interleukin-8 (IL-8) [37,83]. Thesefor targeted adjuvant treatment to inhibit angiogenesis of malignant tumors
; (B) direct inhibition of VEGFR; (C) inhibition of RTK activation of VEGFR
nesis; (E) and antagonizing the stimulators of VEGF via inhibition of EGF; (F)
onoxide; RTK ¼ ; VEGFR ¼ vascular endothelial growth factor receptor.
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b [36], execute their actions by binding to receptors on tumor
cells. Inhibition of this cascade (Fig. 3E) or relative trans-
duction pathway (Fig. 3F) will result in a decrease of VEGF,
and the following angiogenesis.
These targeted agents are still mainly used in advanced
ovarian cancers as an adjunctive regimen of metronomic
chemotherapy. Only sporadic trials have focused on recurrent
uterine cancer and cervical cancer.
Epithelial ovarian cancer
Most of the targeted agents are evaluated first in the
treatment of ovarian cancers, since metronomic schedules of
cytotoxic agents are mainly devised for the treatment of
recurrent ovarian cancers.BevacizumabBevacizumab is a humanized IgG1 monoclonal antibody
that neutralizes VEGF (Fig. 3A). In 2004, it became the first
drug approved solely as an angiogenesis inhibitor, originally
for the treatment of colorectal cancer and later for other
cancers [84]. It is also the drug used in combination with
metronomic chemotherapy that has achieved the most striking
results so far.
It has demonstrated a progression-free survival benefit in
combination with first-line paclitaxel/carboplatin and as main-
tenance therapy in EOC [85]. It was also used as a single agent or
in combinationwith cytotoxic drugs in the treatment of recurrent
EOC patients, yielding an increased response rate and more
months of survival [86]. A dosage of 15 mg/kg every 3 weeks
also showed an improved clinical response in patients [87].
Several studies have illustrated the feasibility of combination
treatment utilizing bevacizumab with a variety of cytotoxic
agents, like oral CTX [88], gemcitabine [89] and platinum [89],
although some tolerable hematologic toxicities occurred [89].
Unique toxicities like proteinuria, hypertension, bleeding,
thromboembolism, wound healing complications, and GI
perforation or fistula have been ascribed to the administration
of bevacizumab and other anti-VEGF molecules for patients
with advanced malignancy. The former 3 toxicities were
generally mild and controllable; the later three are serious,
though uncommon [32].
All the data summarized above support the use of bev-
acizumab, an anti-angiogenic drug, as a single or one of
a combination of agents in the metronomic treatment of
gynecologic cancer.ThalidomideThalidomide is an immune modulator acting on VEGFR to
inhibit angiogenesis (Fig. 1B). It has been investigated
extensively in the treatment of advanced cancers. Significant
activity in multiple myeloma and myelofibrosis syndrome has
been confirmed. A less prominent effect on solid tumors like
Kaposi sarcoma, malignant melanoma, renal cell carcinomaand prostate cancer has been demonstrated, especially in
combination with chemotherapy [90]. There was only limited
activity or even no effect in certain groups of advanced EOC
when daily dosages of 200e400 mg were used alone [91] or in
combination with tamoxifen [92].
On the other hand, the addition of thalidomide (200mg daily)
to topotecan for the treatment of recurrent ovarian cancer was
proved to improve response rates, and is recommended for phase
three trials [93]. Furthermore, daily thalidomide used as
a conjunctive of weekly topotecan (ametronomic schedule) was
studied and accepted as a reasonable alternative to standard
MTD topotecan chemotherapy [94].VandetanibEGFR inhibitors are a new biologically targeted therapy that
may offer newhope in the treatment of patients with advanced or
recurrent ovarian cancers [76]. As a small-molecule receptor
tyrosine kinase inhibitor, vandetanib acts on both VEGFR and
EGFR [95], resulting in the diminishing of both angiogenesis
(Figs. 3C and E) and tumor growth [96]. Its use in dosages of
50 mg/kg daily was proved to be active in a mice ovarian cancer
model when used alone [95] or combined with daily paclitaxel
20 mg/kg intravenously [97]. Though vandetanib 300 mg daily
monotherapy had no significant clinical benefit in some settings
of recurrent EOC, and only tolerable adverse effects like rash,
diarrhea, and a prolonged QT interval, no hypertension was
encountered and its safety in the same setting has been
confirmed [75].More clinical study of this agent in combination
with cytotoxic agents will clarify its effect as an adjunctive
therapy in recurrent EOC. Two other similar agents should be
mentioned here, pazopanib and imatinib.
As another multireceptor tyrosine kinase inhibitor, pazo-
panib can block the function of both VEGFR and EGFR (Figs.
3C and E). In contrast to vandetanib, the combined use of this
agent with metronomic chemotherapy has been evaluated in
mice, and its use (25 mg/kg twice a day or 150 mg/kg daily) in
combination with oral metronomic topotecan (1 mg/kg daily)
showed an excellent anti-tumor effect in an ovarian cancer cell
line by reducing the activity of VEGFR-2 in a dose-dependent
manner [73]. Similar efficacy was found with the combination
of metronomic docetaxel chemotherapy (0.5 mg/kg three
times a week) in dual EGFR and VEGFR inhibition [51].
Imatinib mesylate is a tyrosine kinase inhibitor (Fig. 3E)
with activity against abl, c-kit, and PDGF receptor (PDGFR).
It is not only approved for the treatment of some leukemia and
gastrointestinal stromal tumors, but is also used with gyne-
cologic malignancies with a promising effect either as a single
agent or in combination with metronomic scheduling of
cytotoxic drugs [55].Thrombospondin-1Another possible antiangiogenic choice is inhibition of the
nitric monoxide (NO) signaling pathway (Fig. 3D). NO
induces several important physical functions including
increased vessel diameter, decreased platelet aggregation,
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endogenous NO synthase (eNOS), the primary endogenous
source of NO in endothelial cells, demonstrated a deficiency in
both angiogenesis and permeability response to VEGF in
eNOS-null mice [82]. Therefore, blockage of eNOS has been
considered a promising way to inhibit angiogenesis and tumor
growth.
Thrombospondin (TSP), the first identified endogenous
angiogenesis inhibitor, also controls tissue perfusion, hemo-
stasis and radiosensitivity by antagonizing NO signaling [98].
The TSP family comprises five secreted proteins that have
distinct roles in development and physiology [98]. Among
these secreted proteins, TSP1 is considered a potent angio-
genesis inhibitor. The current Food and Drug Administration-
approved angiogenesis inhibitors, such as ABT-510, a peptide
sequence in the anti-angiogenic type 1 repeats of TSP1, are
expected to inhibit eNOS activation and result in both
decreased NO and angiogenesis.
ABT-510, a promising candidate for the inhibition of tumor
growth, was proved to induce tumor cell apoptosis in mouse
and human ovarian cancer cells [99]. Furthermore, the
regimen of ABT-510 (100 mg/kg daily) in combination with
cisplatin (2 mg/kg per 3 days) or paclitaxel (10 mg/kg every
other day) resulted in a significant increase in the apoptosis of
tumor cells and tumor endothelial cells, and then a decrease in
ovarian tumor size when compared with the use of these
agents alone in a EOC mice model. Through activity on the
tumor vessels, ABT-510 increases the uptake of chemotherapy
drugs and induces the regression of advanced EOC [100].
However, inhibition of the NO pathway may account for
the hypertensive and thrombus adverse events of the VEGF
antagonists; a new TSP analogue that works through the CD47
receptor selectively may prevent these side effects [98].CelecoxibCOX-2 overexpression is associated with poor outcome and
resistance to platinum-based chemotherapy in ovarian cancer.
As a COX-2 inhibitor, celecoxib is believed to decrease VEGF
[101] by blocking the related pathway in tumor cells (Fig. 3F).
Inhibition of COX-2 may also diminish lymph node metastasis
by suppressing VEGF-C-mediated lymph angiogenesis [102].
Celecoxib (400 mg daily) was used in combination with
intravenous carboplatin in recurrent heavily treated EOC
patients with promising activity and tolerable toxicity [103].
In ovarian cancer cell lines, exposure to celecoxib alone
inhibited cellular growth and proliferation in a dose-dependent
manner [104], and when used in combination with cisplatin,
celecoxib demonstrated a clearly antagonistic effect that was
independent of COX-2 expression levels [105]. Other
apoptotic effects of celecoxib on tumor cells might be irrele-
vant to the COX-2 pathway.
The use of celecoxib as a preventive drug for ovarian
cancer is currently being evaluated and has achieved a positive
result, so far [101], and promising results can be expected,
especially when celecoxib is used in combination with
metronomic cytotoxic agents.Hormone therapyEndocrine therapy is a unique and recognized option in the
treatment of chemoresistant ovarian cancer. Synergistic and
additive activities were demonstrated when using tamoxifen
(TAM) combined with cisplatin, doxorubicin, or CTX [106].
Combination endocrine therapy with tamoxifen 20 mg twice
daily and goserelin 3.6 mg subcutaneously once a month was
proved to be an active regimen with minimal toxicity in
platinum-resistant ovarian cancer patients [107].Multitargeted agent regimensA regimen using a combination of thalidomide, imatinib
and celecoxib for up to 24 months following initial chemo-
therapy exhibited excellent results in sporadic young advanced
ovarian cancer victims [108]. It remains to be determined
whether multi-targeted agents or combined agents with
different targets will offer greater clinical benefit than specific
and single VEGF pathway inhibitors [74].Uterine cancerUnlike the case with EOC, the literature on targeted agents
used in uterine malignancy is sparse. Thalidomide was once
used, but no activity in patients with uterine leiomyosarcoma
was demonstrated, nor was any alteration in the VEGF
concentration documented [109]. Vandetanib has shown anti-
tumor effects in a human uterine sarcoma mice model, and the
adverse effects on the tumor-associated microenvironment
have also been demonstrated [110]. However, only a modest
partial response rate was verified when bevacizumab was used
as the only agent in recurrent uterine cancers [111].Cervical cancerLoco-regional control continues to be the main goal in the
treatment of local advanced cervical cancer [112]. Therefore,
targeted agents seem to play the role of radio-sensitizer,
similar to the metronomic cisplatin regimen. The use of cel-
ecoxib in this regard has gained the most attention. Celecoxib
at 400 mg twice daily with concurrent cisplatin, 5-FU MTD
chemotherapy and pelvic radiotherapy presented increased
efficacy but a high incidence of acute toxicities [113] and late
complications [114], which hindered its use for advanced
cervix cancer and paved the way for the combination regimen
of target agents and metronomic chemotherapeutics.
The use of bevacizumab as a single agent [115] or in
combination with cytotoxic drugs was proved to be not only
active but also safe in treating recurrent cervical cancer [116].
However, the identification of more active biologically tar-
geted therapies is warranted for the treatment of advanced
cancer of the cervix [112].
Unsolved problems
Although gynecologic oncologists pay an attention in the use
of metronomic therapy in cancer treatment, there are still many
175W.-H. Su et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 167e178unresolved problems regarding its use. First, the key factor of the
success of this regimenmight be the anti-angiogenic effect of the
continuous use of cytotoxic agents, but the optimal therapeutic
dose is still unknown. The main reason is that we do not have
enough evidence to determine the ‘individualized maximum
repeatable dose’ of every drug we use for circulating endothelial
(progenitor) cells [117]. Second, the role of targeted agents like
COX-2 inhibitors, VEGF inhibitors, or other anti-angiogenic
agents in metronomic therapy are still uncertain and their use
as an adjuvant in metronomic regimens is still being studied. The
same uncertainty also explains why not all anti-angiogenic
agents can be expected to add a therapeutic effect in metro-
nomic therapy [118]. The goal to enroll the best reagent in
combination of metronomic therapy cannot be achieved unless
more in-vitro and in-vivo studies provide more evidence about
the safety profile, the risk of pharmacokinetic/dynamic interfer-
ence, the ease of administration, and costs [117]. Third, it is
difficult to define which population of cancer patients might be
benefited from metronomic therapy and vice versa, and it is also
difficult to determine which combination or schedule might be
the best for patients with certain cancers, for example, gyneco-
logic tumors. Finally, the best biomarker to use for tumor
responsiveness or the prognosis of patients is still under evalua-
tion. The prognostic relevance of TSP-1, bFGF, VEGF, VEGFR
[119] CD31-microvessel density (MVD), VEGF-histoscore
(HS), p53-HS, and TSP1 image analysis score (IA) [120] in
CEOhasbeen evaluated, and tumor-specific cell-freeDNA levels
have been assessed as an indicator of anti-tumor effect [51]. We
need more accurate and reliable markers, like circulating endo-
thelial cells or progenitor endothelial cells, to monitor the anti-
angiogenic effects of these chronic schedules [117] to help
physicians adjust the dosages and time intervals.
Agents used for targeted therapy against tumor cells are
believed to be potent adjuvant agents in metronomic chemo-
therapy and deserve more thorough evaluation. With the
advances in molecular and genetic techniques, relevant infor-
mation on cancers will not only help us identify suitable patients
but also design the proper target drugs [121]. By accumulating
molecular-based knowledge of various and heterogeneous
tumors, clinical trials can be held, negative results avoided, and
more confidence gained [122]. Moreover, the development of
in vitro and in vivo models to test these new therapeutic strate-
gies will certainly help establish stronger preclinical evidence
before clinical trials for these critical patients [121]. However, it
is still difficult for us to study all the genomic components of the
tumors and patients, so computerized simulation might be
a solution to customize the best treatment regimen for individual
patients suffering from a specific cancer.
Conclusion
This review addressed the mechanism of metronomic
chemotherapy in the management of gynecologic cancers.
Gynecologists have seen the successful application of
a number of conventional cytotoxic drugs in this chronic
administration schedule. The term “metronomic” refers
mainly to the schedule, which consists of chronic, equallyspaced, and generally low doses of single or combined
chemotherapeutic drugs without extended drug-free breaks.
The success of metronomic therapy was believed to rely on
continuous administration, activation of cancer immunology,
and antiangiogenic effects. Strategies devised for targeted
adjuvant treatment to inhibit angiogenesis of malignant tumors
include neutralization of circulating growth factors, and inhi-
bition of RTK activation. Though there are still many unre-
solved questions regarding this new treatment regimen, it is
definitely worthy of further research and evaluation, not only
because of its potential to control advanced cancer, but also its
fewer side effects and better life quality for cancer patients.
The explosion in the number of new molecular targets and the
development and application of many powerful technologies
should accelerate the discovery of innovative molecular ther-
apeutics, and eventually result in the identification of new
therapeutic and prognostic targets [123].
Antiangiogenic “metronomic” scheduling of cytotoxic
chemotherapeutics has shown favorable antitumor efficacy
with limited toxicity and better results when combined with
specific angiogenesis targeted agents. With joint efforts
between basic and clinical research, a new paradigm carrying
the prospect of turning cancer into a chronic and controllable
disease can finally be achieved [124].Key issues1. Conventionally, cancer patients are usually treated at or
near the maximum tolerated dose (MTD) with the implicit
intent of eradicating (curing) the tumor after balancing
between efficacy in tumor killing and toxicity to the host.
2. The concept that cancer could be considered as a chronic
disease and might be treated like other chronic diseases to
achieve a status called tumor dormancy is gaining
popularity.
3. The practice, called metronomic therapy, has been
increasing interest in putting more effort into administering
cytotoxic drugs on a more continuous basis, with a much
shorter break period, or none at all, and generally lower
doses of various cytotoxic drugs or combinations with other
newer, targeted therapies, like antiangiogenesis agents.
4. There are still many unresolved problems regarding the
metronomic therapy for gynecologic cancers, including
the optimal therapeutic dose of the antiangiogenic effect of
the continuous use of cytotoxic agents is still unknown;
the role of targeted agents like COX-2 inhibitors, VEGF
inhibitors, or other antiangiogenic agents in metronomic
therapy is still uncertain; and which population of cancer
patients might be benefited from metronomic therapy and
vice versa is difficult to determine; and the better
biomarker to use for tumor responsiveness or the prog-
nosis of patients is still under evaluation.
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